



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Date: 14.11.2022

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Revised Outcome of Board Meeting held on 14th November, 2022

Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 14th November, 2022 have

1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022.

We enclose herewith the Limited Review Report of the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022 issued by the Statutory Auditors of the Company.

The meeting was commenced at 2:00 p.m. and concluded at 2:40 p.m.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited

Jagdish Agrawal
Managing Director

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



Date: 14/11/2022

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 July 2022 to 30 Sep 2022**. (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of

JAYMIN SHAH & ASSOCIATES

Chartered Accountants

CA Mayank Sancheti

M No. :170863

Date: 14/11/2022

Place: Ahmedabad

UDIN: 22170863BDAERR1787



ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170

Website: www.ishitadrugs.com


Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2022

Amount in Lacs except Per Share data

Particulars	Quarter Ended			Half Year Ended		Year Ended	
	3 Months Ended	3 Months Ended	3 Months Ended	6 Months Ended	6 Months Ended	12 Months Ended	
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	
	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22	
1	INCOME						
	Revenue from Operations	283.55	335.36	289.61	618.91	578.54	1409.05
	Other Income	5.28	3.64	5.03	8.92	8.83	10.62
	Total Income	288.83	339.00	294.64	627.84	587.37	1419.67
2	EXPENSES						
(a)	Cost of Material Consumed	217.10	213.30	201.67	430.40	399.32	969.21
(b)	Purchase of Stock-In-Trade	9.45	45.75	5.95	55.20	8.85	50.95
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(19.88)	(18.84)	(6.01)	(38.72)	(10.66)	(2.97)
(d)	Employee Benefit Expense	29.97	29.63	27.15	59.60	54.11	118.08
(e)	Finance Cost	0.16	0.36	1.25	0.52	1.70	2.46
(f)	Depreciation, Depletion and Amortisation Expense	3.24	3.24	3.65	6.49	7.31	12.98
(g)	Other Expense	33.06	43.44	43.05	76.50	91.21	164.66
	Total Other Expenses	33.06	43.44	43.05	76.50	91.21	164.66
	Total Expenses	273.11	316.88	276.72	589.99	551.83	1315.37
3	Total Profit before Exceptional Items and Tax	15.72	22.12	17.92	37.84	35.54	104.30
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5	Total Profit before Tax	15.72	22.12	17.92	37.84	35.54	104.30
6	Tax Expense						
7	Current Tax	4.00	5.50	4.00	9.50	8.00	25.00
8	Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1.20)
9	Total Tax Expenses	4.00	5.50	4.00	9.50	8.00	23.80
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit Loss for the period from continuing operations	11.72	16.62	13.92	28.34	27.54	80.50
12	Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00	0.00
13	Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
14	Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00

Jyotirmayappa



15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
16	Total Profit / (Loss) for the period	11.72	16.62	13.92	28.34	27.54	80.50
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	11.72	16.62	13.92	28.34	27.54	80.50
19	Total profit or loss attributable to						
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to						
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.39	0.56	0.47	0.95	0.92	2.69
	Diluted Earnings / (Loss) per share from continuing operations	0.39	0.56	0.47	0.95	0.92	2.69
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued operation	0.39	0.56	0.47	0.95	0.92	2.69
	Diluted Earnings / (Loss) per share from continuing and discontinued operation	0.39	0.56	0.47	0.95	0.92	2.69
26	Debt Equity Ratio	--	--	--	--	--	--
27	Debt Service Coverage Ratio	--	--	--	--	--	--
28	Interest Service Coverage Ratio	--	--	--	--	--	--

Jyoti Arora



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 14, 2022.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2022 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED****JAGDISH AGRAWAL****MANAGING DIRECTOR****DIN: 01031687**Place **Ahmedabad**Date **14-Nov-22**

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

Statement of Assets and Liabilities

Amount in Lakhs

Particulars	Half Year Ended	Previous Year Ended
	6 Months Ended	12 Months Ended
	Unaudited	Audited
	30-Sep-22	31-Mar-22
ASSETS		
1	Non-current assets	
Property, plant and equipment	82.43	88.46
Capital work-in-progress		
Investment property		
Goodwill		
Other intangible assets		
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
Non-current financial assets	82.43	88.46
Non-current investments	27.15	27.15
Trade receivables, non-current		
Loans, non-current		
Other non-current financial assets	9.57	5.07
Total Non-current financial assets	36.72	32.22
Deferred tax assets (net)		
Other non-current assets		
Total Non-current Assets	119.15	120.67
2	Current assets	
Inventories	128.98	97.37
Current financial assets		
Current investments	398.50	379.32
Trade receivables, current	94.89	54.20
Cash and cash equivalents	16.10	198.68
Bank balance other than cash and cash equivalents	276.54	269.52
Loans, current	0.86	3.30
Other current financial assets	0.38	2.34
Total current financial assets	787.26	907.35
Current tax assets (net)		
Other current assets		
Total Current Assets		
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
TOTAL ASSETS	1035.40	1125.40

Jagdish Agrawal



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	299.03	299.03
	Other equity	588.88	560.53
	Total Equity attributable to owners of Parent	887.91	859.56
	Non controlling interest		
	Total Equity	887.91	859.56
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	0.00	0.00
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	0.00	0.00
	Provisions, non-current		
	Deferred tax liabilities (net)	2.91	2.91
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	2.91	2.91
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	35.42	0.00
	Trade payables, current	62.26	203.88
	Other current financial liabilities	1.96	0.00
	Total current financial liabilities	99.64	203.88
	Other current liabilities	15.33	18.50
	Provisions, current	21.41	8.91
	Current tax liabilities (Net)	8.20	31.63
	Deferred government grants, Current		
	Total current liabilities	44.94	59.04
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities	147.49	265.83
	Total Equity and Liabilities	1035.40	1125.40

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place	Ahmedabad
Date	14-Nov-22

Jagdish Agrawal

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

AUDITED CASH FLOW STATEMENT

Sr. No.	Perticulers	Unaudited Halfyear Ended 30.09.2022 Rs. In Lakhs	Audited Year Ended 31.03.2022 Rs. In Lakhs
(A)	Cash flow from operating activities :		
	Profit before tax	37.84	104.30
	Add : Depreciation	6.49	12.98
	Interest & Other financial charges	0.52	2.46
	Loss on sale of fixed assets	0.00	0.00
	Less : Interest received	6.92	6.82
	Dividend received	0.05	0.04
	Income from Investments	1.88	3.76
	Operating profit before change in working capital	36.00	109.12
	Add : Trade Debtors	(40.69)	98.18
	Decrease/(Increase) in Inventory	(31.61)	(31.93)
	Decrease/(Increase) in Loans and advances	(0.09)	10.85
	Less : Provision for Taxation	9.50	25.00
	Decrease/(Increase) Shore Term Provision	(9.33)	(8.84)
	Decrease/(Increase) Trade Creditors, Current liabilities	163.09	(137.57)
	Net cash generated from operating activities (A)	(199.66)	307.63
(B)	Cash inflow from investing activities :		
	Add : Investment sold / (purchased)	(19.18)	(95.38)
	Dividend received	0.05	0.04
	Income from Investments	1.88	3.76
	Less : Investment in fixed assets	0.47	1.85
	Net cash generated from investing activities (B)	(17.72)	(93.44)
(C)	Cash flow from financial activities :		
	Add : Interest received	6.92	6.82
	Borrowings	35.42	(4.20)
	Less : Interest & Other financial charges	0.52	2.46
	Net cash generated from financial activities (C)	41.82	0.17
	Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	(175.56)	214.36
	Opening balance of Cash and cash equivalents	468.19	253.83
	Closing balance of Cash and cash equivalents	292.64	468.19
	Net Increase/(decrease) in Cash & Cash Equivalents	(175.56)	214.36

Note : Figures in bracket indicate negative value

Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place Ahmedabad

Date 14-Nov-22